B · Normal
On October 24th, Eli Lilly announced data stating that the confirmed objective response rate of SOFE-M combined with bevacizumab in the treatment of ovarian cancer was 79%.
Related telegraphs
[AbbVie: Icritumumab Injection Launched in China] On October 26, AbbVie announce
10-26 10:23
[Eli Lilly: The targeted anti-cancer drug Olomorasib shows durable activity in f
10-25 15:48
[Eli Lilly announced the latest data from the clinical study of the combination
10-11 09:37
[Merck’s PD-1 inhibitor pembrolizumab injection (subcutaneous injection) approve
09-29 16:32
[Junshi Biology: New drugs JS203 and JS207 are expected to start Phase III clini
09-14 13:17
[Hengrui Medicine: Many of its main products will have expanded indications this
09-10 14:42
Comments